search
Back to results

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) (KICKSTART)

Primary Purpose

Non-small Cell Lung Cancer

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Tomivosertib
Pembrolizumab
Pemetrexed
Sponsored by
Effector Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-small Cell Lung Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Inclusion Criteria for Cohort A: Subjects who meet all of the following criteria will be eligible to participate in Cohort A of the study:

1. Have initiated first-line therapy for NSCLC with pembrolizumab and satisfy the following:

  • Have tumor PD-L1 ≥1% by 22C3 IHC;
  • Are judged by the Principal Investigator as tolerating pembrolizumab monotherapy; and
  • Have been on pembrolizumab for at least 3 months (measured from actual first dose date to first dose date of the current study) and the most recent scans are the first scans to objectively demonstrate Progressive Disease per RECIST 1.1
  • The first scan conducted a minimum of 21 days after first dose of anti-PD-(L)1 therapy must have shown either SD, PR, or CR (ie, not Progressive Disease) per RECIST 1.1; and
  • The 2 most recent scans (including 1 demonstrating Progressive Disease) are available to be reviewed

Inclusion Criterion for Cohort B

Subjects who meet the following criterion will be eligible to participate in Cohort B of the study:

1. Are eligible for single-agent pembrolizumab for advanced/metastatic NSCLC in accordance with the package insert and have tumor PD-L1 ≥50% by 22C3 IHC

• Must not have been treated previously with platinum-based chemotherapy in the advanced/metastatic setting. Note: Subjects may have received chemotherapy and/or anti PD (L)1 therapy in the neo/adjuvant setting, provided the last dose of therapy was >9 months prior to randomization.

Subjects who meet the following criterion will be eligible to participate in Cohort C of the study:

1. Have initiated IL therapy for NSCLC and completed all planned (eg, 4 to 6 cycles) platinum-based chemotherapy with at least 2 cycles in combination with pembrolizumab; must not have had progressive disease on tumor staging imaging scans following completion of all planned platinum chemotherapy

  • Are eligible for maintenance therapy with pembrolizumab ± pemetrexed in accordance with the package insert
  • Have tumor PD-L1 ≥1%
  • The last dose of platinum-based chemotherapy must be within 8 weeks of the first dose of the study drug in this study

Inclusion Criterion for All Cohorts

  • Subjects must also meet all of the following criteria to be eligible to participate in the study:

    1. Have histologically confirmed NSCLC that is inoperable, locally advanced or metastatic (Stage IIIb/IV)
    2. Have available at the site a representative formalin-fixed, paraffin-embedded tumor specimen that enabled diagnosis of NSCLC in a tissue block (preferred) or 10 unstained, serial slides, accompanied by an associated pathology report. Note: If the archival tissue is neither sufficient nor available, the subject may still be eligible, upon discussion with the Medical Monitor
    3. Have provided written informed consent and any authorizations required by local law
    4. Are ≥18 years of age
    5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

  1. Have NSCLC with epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations
  2. Have gastrointestinal (GI) disease (eg, gastric or intestinal bypass surgery, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, and/or bowel obstruction) that may interfere with drug absorption or with interpretation of GI AEs
  3. Have known symptomatic brain metastases requiring >10 mg/day of prednisone (or its equivalent). Subjects with previously diagnosed brain metastases are eligible if they have completed their treatment, have recovered from the acute effects of radiation therapy or surgery prior to randomization, fulfill the steroid requirement for these metastases, the 2 most recent serial magnetic resonance imaging (MRI) scans conducted >28 days apart show no central nervous system progression, and are neurologically stable and asymptomatic

Sites / Locations

  • Southern Cancer CenterRecruiting
  • Southern Cancer Center, PC (Mobile Infirmary Circle)
  • Southern Cancer Center, PC (Airport Blvd)Recruiting
  • Southern Cancer Center, PC (Dauphin St)Recruiting
  • Arizona Oncology Associates, PC - HAL (W Bell Rd)
  • Arizona Oncology Associates, PC - NAHOA (W. McDowell)Recruiting
  • Arizona Oncology Associates, PC - HAL
  • Arizona Oncology Associates, PC-NAHOA (N. Windsong)Recruiting
  • Arizona Oncology Associates (N. Pima Rd)
  • Arizona Oncology Associates, PC - HAL
  • Arizona Oncology Associates, PC - HAL
  • Arizona Oncology Associates, PC - HOPE (W. Orange Grove)
  • Arizona Oncology Associates, PC - HOPE (W. Rudasill Rd)
  • Arizona Oncology Associates, PC - HOPE
  • Arizona Oncology Associates, PC - HOPE (West St.)
  • University of California, Los Angeles (UCLA) - AlhambraRecruiting
  • Comprehensive Blood And Cancer CenterRecruiting
  • TOI Clincal Research
  • California Cancer Associates for Research & Excellence (San Diego Pacific Oncology and Hematology Associates) - Encinitas
  • City of Hope - Long Beach Elm
  • Cancer and Blood Specialty ClinicRecruiting
  • University of California, Los Angeles (UCLA)Recruiting
  • USC Norris Comprehensive Cancer CenterRecruiting
  • Mercy Cancer CenterRecruiting
  • Mercy UC Davis Center CenterRecruiting
  • Keck Medicine of USC Norris Oncology/HematologyRecruiting
  • University of California - Irvine Medical Center
  • University of California, Los Angeles (UCLA) - Porter RanchRecruiting
  • St. Mary's Medical Center - San Francisco
  • Dignity Health- SLO Oncology and Hematology
  • University of California, Los Angeles (UCLA) - San Luis ObispoRecruiting
  • California Cancer Associates for Research & Excellence (San Diego Pacific Oncology and Hematology Associates) - San Marcos Cancer Center
  • Mission Hope Cancer Center
  • Dignity Health St. Joseph's Medical Center Stockton
  • Stockton Hematology Oncology Medical Group (Stockton)
  • Santa Clarita - UCLARecruiting
  • Ventura - UCLARecruiting
  • PIH Health Hospital - WhittierRecruiting
  • Rocky Mountain Cancer Centers (South Potomac St)Recruiting
  • Rocky Mountain Cancer Centers (Arapahoe Ave)Recruiting
  • Rocky Mountain Cancer Centers (E Arapahoe Rd)Recruiting
  • Rocky Mountain Cancer CentersRecruiting
  • Rocky Mountain Cancer Centers, Colorado Springs CO (Peregrine)Recruiting
  • Rocky Mountain Cancer Centers (Williams St)Recruiting
  • Rocky Mountain Cancer Centers (E. Hale Parkway)Recruiting
  • Rocky Mountain Cancer Centers (West 2nd Place)Recruiting
  • Rocky Mountain Cancer Centers (W Dry Creek Circle)Recruiting
  • Rocky Mountain Cancer Centers (Ridge Gate Parkway)Recruiting
  • Rocky Mountain Cancer Centers (E. Ken Pratt Blvd)Recruiting
  • Rocky Mountain Cancer Centers (Ridge Gate Parkway)Recruiting
  • Rocky Mountain Cancer Centers (Huron St)Recruiting
  • ASCLEPES Research Centers
  • Memorial Healthcare SystemRecruiting
  • Cancer Care Centers of Brevard (Melbourne)Recruiting
  • University of Florida (UF) Health Cancer Center - Orlando HealthRecruiting
  • Cancer Care Centers of BrevardRecruiting
  • Memorial Cancer Institute at Memorial West HospitalRecruiting
  • Woodlands Medical Specialists, PARecruiting
  • John B. Amos Cancer Center
  • Fort Wayne Medical Oncology and HematologyRecruiting
  • Baptist Health - Lexington
  • Baptist Health - Louisville
  • Luminus Health Research Institute, Inc.
  • Maryland Oncology Hematology, P.A. (Rockledge Dr)Recruiting
  • Maryland Oncology Hematology, P.A. (Matapeake Business Dr)Recruiting
  • Maryland Oncology Hematology, P.A. (Woodyard Rd)Recruiting
  • Maryland Oncology Hematology, P.ARecruiting
  • Maryland Oncology Hematology, P.A. (Thomas Johnson Dr)Recruiting
  • Maryland Oncology Hematology, P.A. (Good Luck Rd)Recruiting
  • Maryland Oncology Hematology, P.A. (Medical Center Drive)Recruiting
  • Maryland Oncology Hematology, P.A. (Healing Way)Recruiting
  • Tufts Medical Center
  • Henry Ford HospitalRecruiting
  • Metro Minnesota CCOPRecruiting
  • Mercy Cancer Center
  • Washington University School of Medicine
  • St. Vincent Frontier Cancer Center
  • Broome Oncology
  • Broome Oncology, LLC (Harrison St)
  • Columbia University Medical Center
  • Columbia UniversityRecruiting
  • Messino Cancer Center
  • Mercy Hematology and Oncology AssociatesRecruiting
  • Gabrail Cancer Center
  • VA Medical Center- DaytonRecruiting
  • Tri-County Hematology & Oncology AssociatesRecruiting
  • Kettering Medical Center
  • Tri-County Hematology & Oncology Associates - MassillonRecruiting
  • University of Toledo
  • Willamette Valley Cancer Institute and Research CtrRecruiting
  • Providence Portland Medical Center
  • Prisma Health Cancer InstituteRecruiting
  • Prairie Lakes Cancer Center
  • Texas Oncology - West Texas (Antilley Rd)Recruiting
  • Texas Oncology-Austin Midtown (W. 38th St)
  • Texas Oncology-Austin Central (Balcones Dr.)
  • Texas Oncology - South Austin
  • Texas Oncology Gulf Coast - Beaumont (College St)
  • Texas Oncology Gulf Coast - Beaumont Mamie McFaddin Ward Cancer Center
  • Texas Oncology - Bedford
  • Texas Oncology-Carrollton (N Josey Lane)
  • Texas Oncology - Dallas Presbyterian HospitalRecruiting
  • Texas Oncology-Baylor Charles A. Sammons Cancer CenterRecruiting
  • Texas Oncology - Denton
  • Texas Oncology - West Texas (Grandview Ave)Recruiting
  • Texas Oncology - West TexasRecruiting
  • Texas Oncology - West Texas (Gateway Blvd E)Recruiting
  • Texas Oncology - West Texas (Joe Battle Dr)Recruiting
  • Texas Oncology - Flower Mound - Carrollton
  • Texas Oncology - Fort Worth Cancer Center
  • Texas Oncology-Grapevine
  • Valley Cancer Associates
  • Texas Oncology - Memorial City
  • Oncology Consultants
  • Texas Oncology Gulf Coast (Willowbrook)
  • Texas Oncology - Longview Cancer CenterRecruiting
  • Texas Oncology - West Texas (Odessa)Recruiting
  • Texas Oncology - PalestineRecruiting
  • Texas Oncology - ParisRecruiting
  • Texas Oncology - Plano EastRecruiting
  • Texas Oncology - TylerRecruiting
  • Texas Oncology - Waco
  • Texas Oncology Golf Coast - Deke Slayton Cancer Center
  • Virginia Cancer Specialists, PC (Kenmore Ave)Recruiting
  • Virginia Cancer Specialists, PC (N George Mason Dr)Recruiting
  • Virginia Cancer Specialists, PCRecruiting
  • Virginia Cancer Specialists, PC (Lake Manassas Dr)Recruiting
  • Virginia Cancer Specialists, PC (Riverside Pkwy)Recruiting
  • Providence Regional Cancer Partnership
  • MultiCare Regional Cancer Center
  • West Virginia University Cancer InstituteRecruiting
  • Gold Coast Cancer Care - PindaraRecruiting
  • Flinders Medical Centre
  • Ballarat Regional Integrated Cancer CenterRecruiting
  • High Technology Hospital MedCenter Ltd - BatumiRecruiting
  • Tbilisi Institute of MedicineRecruiting
  • Evex Hospitals - Kutaisi Referral HospitalRecruiting
  • Healthycore - Israel-Georgia Medical Research Clinic HelsikorRecruiting
  • LLC Todua ClinicRecruiting
  • Ltd Tbilisi State Medical University and Ingorokva High Medical Technology University ClinicRecruiting
  • Mardaleishvili Medical CenterRecruiting
  • Consilium Medulla Multiprofile ClinicRecruiting
  • Evex Hospitals - Caraps MedlineRecruiting
  • Evex Hospitals - Caucasus Medical CenterRecruiting
  • MSB - Medicinski Sistem Beograd
  • University Hospital Medical Center (KBC) Bezanijska Kosa
  • University Clinical Center of Serbia
  • Clinical Center Kragujevac
  • Institute for Pulmonary Diseases of Vojvodina
  • Uzice General Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

A1 Tomi + Current Pembro

Pbo + Current Pembro

B1 Tomi + Pembro

Pbo + Pembro

C1 Tomi + Pembro + Pemetrexed (Non-sqamous) or Tomi + Pembro (Squamous)

Pbo + Pembro + Pemetrexed (Non-sqamous) or Pbo + Pembro (Squamous)

Arm Description

Subjects who have initiated pembrolizumab as a single agent and in accordance with the package insert will receive tomivosertib in addition to pembrolizumab.

Subjects who have initiated pembrolizumab as a single agent and in accordance with the package insert, will receive matching placebo in addition to pembrolizumab.

Subjects will initiate pembrolizumab as first-line therapy and receive tomivosertib.

Subjects will initiate pembrolizumab as first-line therapy and receive matching placebo.

Subjects who have completed 4 to 6 cycles of platinum-based chemotherapy doublet will receive tomi plus pembrolizumab and pemetrexed (non-squamous NSCLC) or tomi plus pembro as a single agent (squamous) in accordance with the package insert.

Subjects who have completed 4 to 6 cycles of platinum-based chemotherapy doublet will receive placebo plus pembrolizumab and pemetrexed (non-squamous NSCLC) or placebo plus pembro as a single agent (squamous) in accordance with the package insert.

Outcomes

Primary Outcome Measures

To characterize the progression-free survival (PFS) of tomivosertib when added to pembrolizumab as a first-line treatment; and
Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier.
To characterize the PFS of tomivosertib when added to pembrolizumab as first line therapy.
Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier.
To characterize the PFS of tomivosertib when added to pembrolizumab and pemetrexed in non-squamous NSCLC, and pembrolizumab in squamous NSCLC as first line maintenance therapy.
Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier.

Secondary Outcome Measures

To characterize the PFS of tomivosertib when added to pembrolizumab in Cohorts A, B, and B C individually and combined
Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier.
To characterize the PFS of tomivosertib when added to pembrolizumab as a first-line treatment in subjects with NSCLC
Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier. Objective response per RECIST 1.1, as assessed by the BIRC.
To characterize the PFS of tomivosertib when added to pembrolizumab and pemetrexed in non-squamous NSCLC, and pembrolizumab in squamous NSCLC as a first-line maintenance treatment in subjects with NSCLC.
Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier. Objective response per RECIST 1.1, as assessed by the BIRC.
To characterize the PFS of tomivosertib when added to pembrolizumab after first radiographic progression on pembrolizumab monotherapy
Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier. Objective response per RECIST 1.1, as assessed by the BIRC

Full Information

First Posted
November 3, 2020
Last Updated
September 22, 2023
Sponsor
Effector Therapeutics
Collaborators
Medpace, Inc., ICON plc
search

1. Study Identification

Unique Protocol Identification Number
NCT04622007
Brief Title
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
Acronym
KICKSTART
Official Title
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 2, 2021 (Actual)
Primary Completion Date
March 15, 2024 (Anticipated)
Study Completion Date
May 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Effector Therapeutics
Collaborators
Medpace, Inc., ICON plc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Tomivosertib combined with pembrolizumab in Subjects with PD-L1 positive NSCLC
Detailed Description
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-small Cell Lung Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
In each Cohort approximately 60 eligible Subjects will be randomized to receive tomivosertib or matching placebo in combination with pembrolizumab. Cohorts A and C are not currently enrolling. In Cohort B, subjects will receive blinded IP (tomivosertib or matching placebo) in combination with pembrolizumab as first line therapy.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
In all cohorts, investigational product (IP, tomivosertib or placebo) will be blinded and pembrolizumab will be open label. On Cohort C, pembrolizumab and pemetrexed will be open label.
Allocation
Randomized
Enrollment
180 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
A1 Tomi + Current Pembro
Arm Type
Experimental
Arm Description
Subjects who have initiated pembrolizumab as a single agent and in accordance with the package insert will receive tomivosertib in addition to pembrolizumab.
Arm Title
Pbo + Current Pembro
Arm Type
Placebo Comparator
Arm Description
Subjects who have initiated pembrolizumab as a single agent and in accordance with the package insert, will receive matching placebo in addition to pembrolizumab.
Arm Title
B1 Tomi + Pembro
Arm Type
Experimental
Arm Description
Subjects will initiate pembrolizumab as first-line therapy and receive tomivosertib.
Arm Title
Pbo + Pembro
Arm Type
Placebo Comparator
Arm Description
Subjects will initiate pembrolizumab as first-line therapy and receive matching placebo.
Arm Title
C1 Tomi + Pembro + Pemetrexed (Non-sqamous) or Tomi + Pembro (Squamous)
Arm Type
Experimental
Arm Description
Subjects who have completed 4 to 6 cycles of platinum-based chemotherapy doublet will receive tomi plus pembrolizumab and pemetrexed (non-squamous NSCLC) or tomi plus pembro as a single agent (squamous) in accordance with the package insert.
Arm Title
Pbo + Pembro + Pemetrexed (Non-sqamous) or Pbo + Pembro (Squamous)
Arm Type
Placebo Comparator
Arm Description
Subjects who have completed 4 to 6 cycles of platinum-based chemotherapy doublet will receive placebo plus pembrolizumab and pemetrexed (non-squamous NSCLC) or placebo plus pembro as a single agent (squamous) in accordance with the package insert.
Intervention Type
Drug
Intervention Name(s)
Tomivosertib
Other Intervention Name(s)
eFT508
Intervention Description
Tomivosertib (eFT508) will be taken at 100 mg twice daily (bid) with meals
Intervention Type
Biological
Intervention Name(s)
Pembrolizumab
Other Intervention Name(s)
Keytruda®
Intervention Description
Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.
Intervention Type
Drug
Intervention Name(s)
Pemetrexed
Other Intervention Name(s)
Alimta®
Intervention Description
Subjects will initiate pemetrexed at 500 mg/m2 intravenously (IV) at a frequency of every 3 weeks.
Primary Outcome Measure Information:
Title
To characterize the progression-free survival (PFS) of tomivosertib when added to pembrolizumab as a first-line treatment; and
Description
Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier.
Time Frame
2 years
Title
To characterize the PFS of tomivosertib when added to pembrolizumab as first line therapy.
Description
Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier.
Time Frame
2 years
Title
To characterize the PFS of tomivosertib when added to pembrolizumab and pemetrexed in non-squamous NSCLC, and pembrolizumab in squamous NSCLC as first line maintenance therapy.
Description
Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
To characterize the PFS of tomivosertib when added to pembrolizumab in Cohorts A, B, and B C individually and combined
Description
Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier.
Time Frame
2 years
Title
To characterize the PFS of tomivosertib when added to pembrolizumab as a first-line treatment in subjects with NSCLC
Description
Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier. Objective response per RECIST 1.1, as assessed by the BIRC.
Time Frame
2 years
Title
To characterize the PFS of tomivosertib when added to pembrolizumab and pemetrexed in non-squamous NSCLC, and pembrolizumab in squamous NSCLC as a first-line maintenance treatment in subjects with NSCLC.
Description
Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier. Objective response per RECIST 1.1, as assessed by the BIRC.
Time Frame
2 years
Title
To characterize the PFS of tomivosertib when added to pembrolizumab after first radiographic progression on pembrolizumab monotherapy
Description
Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier. Objective response per RECIST 1.1, as assessed by the BIRC
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Inclusion Criteria for Cohort A: Subjects who meet all of the following criteria will be eligible to participate in Cohort A of the study: 1. Have initiated first-line therapy for NSCLC with pembrolizumab and satisfy the following: Have tumor PD-L1 ≥1% by 22C3 IHC; Are judged by the Principal Investigator as tolerating pembrolizumab monotherapy; and Have been on pembrolizumab for at least 3 months (measured from actual first dose date to first dose date of the current study) and the most recent scans are the first scans to objectively demonstrate Progressive Disease per RECIST 1.1 The first scan conducted a minimum of 21 days after first dose of anti-PD-(L)1 therapy must have shown either SD, PR, or CR (ie, not Progressive Disease) per RECIST 1.1; and The 2 most recent scans (including 1 demonstrating Progressive Disease) are available to be reviewed Inclusion Criterion for Cohort B Subjects who meet the following criterion will be eligible to participate in Cohort B of the study: 1. Are eligible for single-agent pembrolizumab for advanced/metastatic NSCLC in accordance with the package insert and have tumor PD-L1 ≥50% by 22C3 IHC • Must not have been treated previously with platinum-based chemotherapy in the advanced/metastatic setting. Note: Subjects may have received chemotherapy and/or anti PD (L)1 therapy in the neo/adjuvant setting, provided the last dose of therapy was >9 months prior to randomization. All cohorts require PD-L1 testing (TPS as determined by an FDA-approved test: subjects in Cohort B must specifically have PD-L1 testing using the PD-L1 IHC 22C3 pharmDx test kit). Subjects in Cohort B for whom PD-L1 testing was not performed with the required IHC 22C3 pharmDx test kit may be randomized if all other study criteria have been met, pending retest with the required IHC 22C3 pharmDx test kit. Subjects who meet the following criterion will be eligible to participate in Cohort C of the study: 1. Have initiated IL therapy for NSCLC and completed all planned (eg, 4 to 6 cycles) platinum-based chemotherapy with at least 2 cycles in combination with pembrolizumab; must not have had progressive disease on tumor staging imaging scans following completion of all planned platinum chemotherapy Are eligible for maintenance therapy with pembrolizumab ± pemetrexed in accordance with the package insert Have tumor PD-L1 ≥1% The last dose of platinum-based chemotherapy must be within 8 weeks of the first dose of the study drug in this study Inclusion Criterion for All Cohorts Subjects must also meet all of the following criteria to be eligible to participate in the study: Have histologically confirmed NSCLC that is inoperable, locally advanced or metastatic (Stage IIIb/IV) Have available at the site a representative formalin-fixed, paraffin-embedded tumor specimen that enabled diagnosis of NSCLC in a tissue block (preferred) or 10 unstained, serial slides, accompanied by an associated pathology report. Note: If the archival tissue is neither sufficient nor available, the subject may still be eligible, upon discussion with the Medical Monitor Have provided written informed consent and any authorizations required by local law Are ≥18 years of age Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Exclusion Criteria: Have NSCLC with epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations Have gastrointestinal (GI) disease (eg, gastric or intestinal bypass surgery, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, and/or bowel obstruction) that may interfere with drug absorption or with interpretation of GI AEs Have known symptomatic brain metastases requiring >10 mg/day of prednisone (or its equivalent). Subjects with previously diagnosed brain metastases are eligible if they have completed their treatment, have recovered from the acute effects of radiation therapy or surgery prior to randomization, fulfill the steroid requirement for these metastases, the 2 most recent serial magnetic resonance imaging (MRI) scans conducted >28 days apart show no central nervous system progression, and are neurologically stable and asymptomatic
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mark Densel
Phone
858-925-8215
Email
clinicaltrials@effector.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Douglas Warner, MD
Organizational Affiliation
EFFECTOR Therapeutics, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Southern Cancer Center
City
Daphne
State/Province
Alabama
ZIP/Postal Code
36526
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karla Childers
Phone
251-607-5283
Email
karla.childers@usoncology.com
First Name & Middle Initial & Last Name & Degree
Michael Meshad, MD
Facility Name
Southern Cancer Center, PC (Mobile Infirmary Circle)
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36607
Country
United States
Individual Site Status
Completed
Facility Name
Southern Cancer Center, PC (Airport Blvd)
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36608
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karla Childers
Phone
251-607-5283
Email
karla.childers@usoncology.com
First Name & Middle Initial & Last Name & Degree
Michael Meshad, MD
Facility Name
Southern Cancer Center, PC (Dauphin St)
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36608
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karla Childers
Phone
251-607-5283
Email
karla.childers@usoncology.com
First Name & Middle Initial & Last Name & Degree
Michael Meshad, MA
Facility Name
Arizona Oncology Associates, PC - HAL (W Bell Rd)
City
Glendale
State/Province
Arizona
ZIP/Postal Code
85308
Country
United States
Individual Site Status
Completed
Facility Name
Arizona Oncology Associates, PC - NAHOA (W. McDowell)
City
Goodyear
State/Province
Arizona
ZIP/Postal Code
85395
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amanda Navarro
Phone
623-204-9953
Email
Amanda.Navarro@usoncology.com
First Name & Middle Initial & Last Name & Degree
Govardhanan Nagaiah, MD
Facility Name
Arizona Oncology Associates, PC - HAL
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85016
Country
United States
Individual Site Status
Completed
Facility Name
Arizona Oncology Associates, PC-NAHOA (N. Windsong)
City
Prescott Valley
State/Province
Arizona
ZIP/Postal Code
86314
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erika Arguello
Phone
480-276-5119
Email
Erika.ArguelloVargas@usoncology.com
First Name & Middle Initial & Last Name & Degree
Govardhanan Nagaiah, MD
Facility Name
Arizona Oncology Associates (N. Pima Rd)
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85258
Country
United States
Individual Site Status
Completed
Facility Name
Arizona Oncology Associates, PC - HAL
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85258
Country
United States
Individual Site Status
Completed
Facility Name
Arizona Oncology Associates, PC - HAL
City
Tempe
State/Province
Arizona
ZIP/Postal Code
85284
Country
United States
Individual Site Status
Completed
Facility Name
Arizona Oncology Associates, PC - HOPE (W. Orange Grove)
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85704
Country
United States
Individual Site Status
Completed
Facility Name
Arizona Oncology Associates, PC - HOPE (W. Rudasill Rd)
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85704
Country
United States
Individual Site Status
Completed
Facility Name
Arizona Oncology Associates, PC - HOPE
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85711
Country
United States
Individual Site Status
Completed
Facility Name
Arizona Oncology Associates, PC - HOPE (West St.)
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85745
Country
United States
Individual Site Status
Completed
Facility Name
University of California, Los Angeles (UCLA) - Alhambra
City
Alhambra
State/Province
California
ZIP/Postal Code
91801
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Helene Yang
Phone
626-588-2825
Ext
16407
Email
hyang@mednet.ucla.edu
First Name & Middle Initial & Last Name & Degree
Aaron Lisberg, MD
Facility Name
Comprehensive Blood And Cancer Center
City
Bakersfield
State/Province
California
ZIP/Postal Code
93309
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Carrillo
Phone
661-862-8548
Email
mcarrillo@cbccusa.com
First Name & Middle Initial & Last Name & Degree
Ravindranath Patel, MD
Facility Name
TOI Clincal Research
City
Cerritos
State/Province
California
ZIP/Postal Code
90703
Country
United States
Individual Site Status
Completed
Facility Name
California Cancer Associates for Research & Excellence (San Diego Pacific Oncology and Hematology Associates) - Encinitas
City
Encinitas
State/Province
California
ZIP/Postal Code
92024
Country
United States
Individual Site Status
Completed
Facility Name
City of Hope - Long Beach Elm
City
Long Beach
State/Province
California
ZIP/Postal Code
90813
Country
United States
Individual Site Status
Completed
Facility Name
Cancer and Blood Specialty Clinic
City
Los Alamitos
State/Province
California
ZIP/Postal Code
90720
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mimi Washington
Phone
562-735-0602
Email
miwashington@mednet.ucla.edu
First Name & Middle Initial & Last Name & Degree
Nihal Abdulla, MD
Facility Name
University of California, Los Angeles (UCLA)
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tina Tieu
Phone
310-633-8400
Email
TinaTieu@mednet.ucla.edu
First Name & Middle Initial & Last Name & Degree
Aaron Lisberg, MD
Facility Name
USC Norris Comprehensive Cancer Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Azucena Vera
Phone
323-865-0421
Email
Azucena.Vera@med.usc.edu
First Name & Middle Initial & Last Name & Degree
Jorge Nieva, MD
Facility Name
Mercy Cancer Center
City
Merced
State/Province
California
ZIP/Postal Code
95340
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tirath Sanghera
Phone
209-564-3607
Email
tirath.sanghera@commonspirit.org
First Name & Middle Initial & Last Name & Degree
Sidhu Parminder, MD
Facility Name
Mercy UC Davis Center Center
City
Merced
State/Province
California
ZIP/Postal Code
95340
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tirath Sanghera
Phone
209-564-3607
Email
tirath.sanghera@commonspirit.org
First Name & Middle Initial & Last Name & Degree
Parminder Sidhu, MD
Facility Name
Keck Medicine of USC Norris Oncology/Hematology
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrew Zeng
Phone
323-865-0490
Email
andrew.zeng@med.usc.edu
First Name & Middle Initial & Last Name & Degree
Jorge Nieva, MD
Facility Name
University of California - Irvine Medical Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Individual Site Status
Completed
Facility Name
University of California, Los Angeles (UCLA) - Porter Ranch
City
Porter Ranch
State/Province
California
ZIP/Postal Code
91326
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Audrey Roque-Tayag
Phone
818-271-2500
Ext
16677
Email
artayag@mednet.ucla.edu
First Name & Middle Initial & Last Name & Degree
Aaron Lisberg, MD
Facility Name
St. Mary's Medical Center - San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94117
Country
United States
Individual Site Status
Completed
Facility Name
Dignity Health- SLO Oncology and Hematology
City
San Luis Obispo
State/Province
California
ZIP/Postal Code
93401
Country
United States
Individual Site Status
Completed
Facility Name
University of California, Los Angeles (UCLA) - San Luis Obispo
City
San Luis Obispo
State/Province
California
ZIP/Postal Code
93401
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Mejia
Phone
805-541-8252
Ext
15192
Email
alisberg@mednet.ucla.edu
First Name & Middle Initial & Last Name & Degree
Aaron Lisberg, MD
Facility Name
California Cancer Associates for Research & Excellence (San Diego Pacific Oncology and Hematology Associates) - San Marcos Cancer Center
City
San Marcos
State/Province
California
ZIP/Postal Code
92069
Country
United States
Individual Site Status
Completed
Facility Name
Mission Hope Cancer Center
City
Santa Maria
State/Province
California
ZIP/Postal Code
93454
Country
United States
Individual Site Status
Completed
Facility Name
Dignity Health St. Joseph's Medical Center Stockton
City
Stockton
State/Province
California
ZIP/Postal Code
95204
Country
United States
Individual Site Status
Completed
Facility Name
Stockton Hematology Oncology Medical Group (Stockton)
City
Stockton
State/Province
California
ZIP/Postal Code
95204
Country
United States
Individual Site Status
Completed
Facility Name
Santa Clarita - UCLA
City
Valencia
State/Province
California
ZIP/Postal Code
91355
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katie Orefice
Phone
661-255-5350
Ext
16351
Email
korefice@mednet.ucla.edu
First Name & Middle Initial & Last Name & Degree
Aaron Lisberg, MD
Facility Name
Ventura - UCLA
City
Ventura
State/Province
California
ZIP/Postal Code
93003
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacob Medina
Phone
424-402-9553
Email
jacobmedina@mednet.ucla.edu
First Name & Middle Initial & Last Name & Degree
Aaron Lisberg, MD
Facility Name
PIH Health Hospital - Whittier
City
Whittier
State/Province
California
ZIP/Postal Code
90602
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gayle Madden-Mathes
Phone
562-698-0811
Ext
13488
Email
Gayle.MaddenMathes@pihhealth.org
First Name & Middle Initial & Last Name & Degree
Lisa Wang, MD
Facility Name
Rocky Mountain Cancer Centers (South Potomac St)
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80012
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lynne Boynton
Phone
303-730-4751
Email
lynne.boynton@usoncology.com
First Name & Middle Initial & Last Name & Degree
Jesal Patel, MD
Facility Name
Rocky Mountain Cancer Centers (Arapahoe Ave)
City
Boulder
State/Province
Colorado
ZIP/Postal Code
80303
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bobbie Donnachaidh
Phone
303-925-0700
Email
bobbie.donnachaidh@usoncology.com
First Name & Middle Initial & Last Name & Degree
Jesal Patel, MD
Facility Name
Rocky Mountain Cancer Centers (E Arapahoe Rd)
City
Centennial
State/Province
Colorado
ZIP/Postal Code
80112
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bobbie Donnachaidh
Phone
303-925-0700
Email
bobbie.donnachaidh@usoncology.com
First Name & Middle Initial & Last Name & Degree
Jesal Patel, MD
Facility Name
Rocky Mountain Cancer Centers
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80907
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara Vigen
Phone
719-667-6966
Email
Sara.Vigen@usoncology.com
First Name & Middle Initial & Last Name & Degree
Jesal C. Patel, MD
Facility Name
Rocky Mountain Cancer Centers, Colorado Springs CO (Peregrine)
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80923
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kathy Schleich
Phone
303-285-5018
Email
Katherine.Schleich@USOncology.com
First Name & Middle Initial & Last Name & Degree
Jesal Patel, MD
Facility Name
Rocky Mountain Cancer Centers (Williams St)
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Therese Jones
Phone
303-388-4876
Email
therese.jones@usoncology.com
First Name & Middle Initial & Last Name & Degree
Jesal Patel, MD
Facility Name
Rocky Mountain Cancer Centers (E. Hale Parkway)
City
Denver
State/Province
Colorado
ZIP/Postal Code
80220
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kathy Schleich
Phone
719-296-6000
Email
katherine.schleich@usoncology.com
First Name & Middle Initial & Last Name & Degree
Jesal Patel, MD
Facility Name
Rocky Mountain Cancer Centers (West 2nd Place)
City
Lakewood
State/Province
Colorado
ZIP/Postal Code
80228
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara Vigen
Phone
719-667-6966
Email
Sara.Vigen@usoncology.com
First Name & Middle Initial & Last Name & Degree
Jesal Patel, MD
Facility Name
Rocky Mountain Cancer Centers (W Dry Creek Circle)
City
Littleton
State/Province
Colorado
ZIP/Postal Code
80120-4413
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lynne Boynton
Phone
303-730-4751
Email
lynne.boynton@usoncology.com
First Name & Middle Initial & Last Name & Degree
Jesal Patel, MD
Facility Name
Rocky Mountain Cancer Centers (Ridge Gate Parkway)
City
Lone Tree
State/Province
Colorado
ZIP/Postal Code
80124
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bethany Glatthar
Phone
303-925-0700
Email
bethany.glatthar@usoncology.com
First Name & Middle Initial & Last Name & Degree
Jesal Patel, MD
Facility Name
Rocky Mountain Cancer Centers (E. Ken Pratt Blvd)
City
Longmont
State/Province
Colorado
ZIP/Postal Code
80504
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Hege
Phone
303-386-7622
Email
jennifer.hege@usoncology.com
First Name & Middle Initial & Last Name & Degree
Jesal Patel, MD
Facility Name
Rocky Mountain Cancer Centers (Ridge Gate Parkway)
City
Pueblo
State/Province
Colorado
ZIP/Postal Code
81008
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara Vigen
Phone
719-667-6966
Email
Sara.Vigen@usoncology.com
First Name & Middle Initial & Last Name & Degree
Jesal Patel, MD
Facility Name
Rocky Mountain Cancer Centers (Huron St)
City
Thornton
State/Province
Colorado
ZIP/Postal Code
80260
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Hege
Phone
303-386-7622
Email
jennifer.hege@usoncology.com
First Name & Middle Initial & Last Name & Degree
Jesal Patel, MD
Facility Name
ASCLEPES Research Centers
City
Brooksville
State/Province
Florida
ZIP/Postal Code
34613
Country
United States
Individual Site Status
Completed
Facility Name
Memorial Healthcare System
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andres Alvarez
Phone
954-265-1841
Email
AndrAlvarez@mhs.net
First Name & Middle Initial & Last Name & Degree
Luiz Raez, MD
Facility Name
Cancer Care Centers of Brevard (Melbourne)
City
Melbourne
State/Province
Florida
ZIP/Postal Code
32935
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karla Childers
Phone
251-607-5283
Email
karla.childers@usoncology.com
First Name & Middle Initial & Last Name & Degree
Pavan Kancharla, MD
Facility Name
University of Florida (UF) Health Cancer Center - Orlando Health
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Ribacchi
Phone
321-841-7031
Email
Stephanie.Ribacchi@orlandohealth.com
First Name & Middle Initial & Last Name & Degree
Jennifer Tseng, MD
Facility Name
Cancer Care Centers of Brevard
City
Palm Bay
State/Province
Florida
ZIP/Postal Code
32901
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Deborah Schmitt
Phone
321-405-1022
Email
deborah.schmitt@usoncology.com
First Name & Middle Initial & Last Name & Degree
Pavan Kancharla, MD
Facility Name
Memorial Cancer Institute at Memorial West Hospital
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33028
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andres Alvarez
Phone
954-265-1841
Email
AndrAlvarez@mhs.net
First Name & Middle Initial & Last Name & Degree
Luis Raez, MD
Facility Name
Woodlands Medical Specialists, PA
City
Pensacola
State/Province
Florida
ZIP/Postal Code
32503
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leslie Bellamy
Phone
850-696-4423
Email
lbellamy@woodlandsmed.com
First Name & Middle Initial & Last Name & Degree
Rami Owera, MD
Facility Name
John B. Amos Cancer Center
City
Columbus
State/Province
Georgia
ZIP/Postal Code
31904
Country
United States
Individual Site Status
Completed
Facility Name
Fort Wayne Medical Oncology and Hematology
City
Fort Wayne
State/Province
Indiana
ZIP/Postal Code
46804
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Raven Carter
Phone
260-969-7876
Email
Raven.carter@fwmoh.com
First Name & Middle Initial & Last Name & Degree
Ahad Sadiq, MD
Facility Name
Baptist Health - Lexington
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40503
Country
United States
Individual Site Status
Completed
Facility Name
Baptist Health - Louisville
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40207
Country
United States
Individual Site Status
Completed
Facility Name
Luminus Health Research Institute, Inc.
City
Annapolis
State/Province
Maryland
ZIP/Postal Code
21401
Country
United States
Individual Site Status
Completed
Facility Name
Maryland Oncology Hematology, P.A. (Rockledge Dr)
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20817
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kanchalita Ngo
Phone
240-826-2120
Email
kanchalita.ngo@usoncology.com
First Name & Middle Initial & Last Name & Degree
Mohit Narang, MD
Facility Name
Maryland Oncology Hematology, P.A. (Matapeake Business Dr)
City
Brandywine
State/Province
Maryland
ZIP/Postal Code
20613
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Cipriano
Phone
301-812-3900
Email
jennifer.cipriano@usoncology.com
First Name & Middle Initial & Last Name & Degree
Mohit Narang, MD
Facility Name
Maryland Oncology Hematology, P.A. (Woodyard Rd)
City
Clinton
State/Province
Maryland
ZIP/Postal Code
20735
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nia Moses
Phone
301-868-2285
Email
nia.moses@usoncology.com
First Name & Middle Initial & Last Name & Degree
Mohit Narang, MD
Facility Name
Maryland Oncology Hematology, P.A
City
Columbia
State/Province
Maryland
ZIP/Postal Code
21044
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Teresa Saavedra
Phone
410-964-2212
Email
Teresa.Saavedra@usoncology.com
First Name & Middle Initial & Last Name & Degree
Mohit Narang, MD
Facility Name
Maryland Oncology Hematology, P.A. (Thomas Johnson Dr)
City
Frederick
State/Province
Maryland
ZIP/Postal Code
21702
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kevin Maguire
Phone
240-826-2115
Email
Kevin.Maguire@usoncology.com
First Name & Middle Initial & Last Name & Degree
Mohit Narang, MD
Facility Name
Maryland Oncology Hematology, P.A. (Good Luck Rd)
City
Lanham
State/Province
Maryland
ZIP/Postal Code
20706
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Cipriano
Phone
301-812-3900
Email
jennifer.cipriano@usoncology.com
First Name & Middle Initial & Last Name & Degree
Mohit Narang, MD
Facility Name
Maryland Oncology Hematology, P.A. (Medical Center Drive)
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20850
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandra Brown-Flannery
Phone
301-424-6231
Email
ali.brown-flannery@usoncology.com
First Name & Middle Initial & Last Name & Degree
Mohit Narang, MD
Facility Name
Maryland Oncology Hematology, P.A. (Healing Way)
City
Silver Spring
State/Province
Maryland
ZIP/Postal Code
20904
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Madi Gaudieri
Phone
301-933-3216
Ext
4718
Email
madi.gaudieri@usoncology.com
First Name & Middle Initial & Last Name & Degree
Mohit Narang, MD
Facility Name
Tufts Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02111
Country
United States
Individual Site Status
Completed
Facility Name
Henry Ford Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marybeth McCarthy
Phone
313-725-7855
Email
mMcCart2@hfhs.org
First Name & Middle Initial & Last Name & Degree
Shirish Gadgeel, MD
Facility Name
Metro Minnesota CCOP
City
Saint Louis Park
State/Province
Minnesota
ZIP/Postal Code
55416
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hannah Merill
Phone
952-993-0996
Email
hannah.merrill@parknicollet.com
First Name & Middle Initial & Last Name & Degree
Yan Ji, MD
Facility Name
Mercy Cancer Center
City
Joplin
State/Province
Missouri
ZIP/Postal Code
64804
Country
United States
Individual Site Status
Completed
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Completed
Facility Name
St. Vincent Frontier Cancer Center
City
Billings
State/Province
Montana
ZIP/Postal Code
59102
Country
United States
Individual Site Status
Completed
Facility Name
Broome Oncology
City
Binghamton
State/Province
New York
ZIP/Postal Code
13905
Country
United States
Individual Site Status
Completed
Facility Name
Broome Oncology, LLC (Harrison St)
City
Johnson City
State/Province
New York
ZIP/Postal Code
13790
Country
United States
Individual Site Status
Completed
Facility Name
Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Completed
Facility Name
Columbia University
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tom Lehan
Phone
212-305-5049
Email
tl3115@cumc.columbia.edu
First Name & Middle Initial & Last Name & Degree
Brian Henick, MD
Facility Name
Messino Cancer Center
City
Asheville
State/Province
North Carolina
ZIP/Postal Code
28806
Country
United States
Individual Site Status
Completed
Facility Name
Mercy Hematology and Oncology Associates
City
Canton
State/Province
Ohio
ZIP/Postal Code
44708
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joan Kaufman, RN BSN OCN
Phone
330-489-1274
Email
kaufmaj3@ccf.org
First Name & Middle Initial & Last Name & Degree
Mitchel Haut, MD
Facility Name
Gabrail Cancer Center
City
Canton
State/Province
Ohio
ZIP/Postal Code
44718
Country
United States
Individual Site Status
Completed
Facility Name
VA Medical Center- Dayton
City
Dayton
State/Province
Ohio
ZIP/Postal Code
45428
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kelly Nadar
Phone
937-268-6511
Ext
5987
First Name & Middle Initial & Last Name & Degree
Albert Malcom, MD
Facility Name
Tri-County Hematology & Oncology Associates
City
Dover
State/Province
Ohio
ZIP/Postal Code
44622
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joan Kaufman
Phone
330-489-1274
Email
kaufmaj3@ccf.org
First Name & Middle Initial & Last Name & Degree
Nagaprasad Nagajothi, MD
Facility Name
Kettering Medical Center
City
Kettering
State/Province
Ohio
ZIP/Postal Code
45429
Country
United States
Individual Site Status
Completed
Facility Name
Tri-County Hematology & Oncology Associates - Massillon
City
Massillon
State/Province
Ohio
ZIP/Postal Code
44646
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joan Kaufman
Phone
330-489-1274
Email
KAUFMAJ3@ccf.org
First Name & Middle Initial & Last Name & Degree
Nagaprasad Nagajothi, MD
Facility Name
University of Toledo
City
Toledo
State/Province
Ohio
ZIP/Postal Code
43614
Country
United States
Individual Site Status
Completed
Facility Name
Willamette Valley Cancer Institute and Research Ctr
City
Eugene
State/Province
Oregon
ZIP/Postal Code
97401
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jordan Montagano
Phone
541-988-7939
Ext
1369
Email
jeanne.schaffer@usoncology.com
First Name & Middle Initial & Last Name & Degree
James Butrynski, MD
Facility Name
Providence Portland Medical Center
City
Portland
State/Province
Oregon
ZIP/Postal Code
97213
Country
United States
Individual Site Status
Completed
Facility Name
Prisma Health Cancer Institute
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29615
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kim Williams
Phone
864-241-7272
Email
kim.williams3@prismahealth.org
First Name & Middle Initial & Last Name & Degree
Britt Bolemon, MD
Facility Name
Prairie Lakes Cancer Center
City
Watertown
State/Province
South Dakota
ZIP/Postal Code
57201
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology - West Texas (Antilley Rd)
City
Abilene
State/Province
Texas
ZIP/Postal Code
79606-5208
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rebecca Garcia
Phone
325-692-0188
Email
becky.garcia@usoncology.com
First Name & Middle Initial & Last Name & Degree
Pankaj Khandelwal, MD
Facility Name
Texas Oncology-Austin Midtown (W. 38th St)
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology-Austin Central (Balcones Dr.)
City
Austin
State/Province
Texas
ZIP/Postal Code
78731
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology - South Austin
City
Austin
State/Province
Texas
ZIP/Postal Code
78745
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology Gulf Coast - Beaumont (College St)
City
Beaumont
State/Province
Texas
ZIP/Postal Code
77701
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology Gulf Coast - Beaumont Mamie McFaddin Ward Cancer Center
City
Beaumont
State/Province
Texas
ZIP/Postal Code
77702
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology - Bedford
City
Bedford
State/Province
Texas
ZIP/Postal Code
76022
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology-Carrollton (N Josey Lane)
City
Carlton
State/Province
Texas
ZIP/Postal Code
75010
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology - Dallas Presbyterian Hospital
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nancy Jones
Phone
214-265-2067
First Name & Middle Initial & Last Name & Degree
Kristi McIntyre, MD
Facility Name
Texas Oncology-Baylor Charles A. Sammons Cancer Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophia Macabare
Phone
214-370-1763
Email
sophia.macabare@usoncology.com
First Name & Middle Initial & Last Name & Degree
Kartik Konduri, MD
Facility Name
Texas Oncology - Denton
City
Denton
State/Province
Texas
ZIP/Postal Code
76201
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology - West Texas (Grandview Ave)
City
El Paso
State/Province
Texas
ZIP/Postal Code
79902
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tanya Jauch Worley
Phone
915-747-4878
Email
tanya.jauchworley@usoncology.com
First Name & Middle Initial & Last Name & Degree
Pankaj Khandelwal, MD
Facility Name
Texas Oncology - West Texas
City
El Paso
State/Province
Texas
ZIP/Postal Code
79902
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mary Williams
Phone
432-688-0821
Email
mary.williams2@usoncology.com
First Name & Middle Initial & Last Name & Degree
Pankaj Khandelwal, MD
Facility Name
Texas Oncology - West Texas (Gateway Blvd E)
City
El Paso
State/Province
Texas
ZIP/Postal Code
79915
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tanya Jauch Worley
Phone
915-747-4878
Email
tanya.jauchworley@usoncology.com
First Name & Middle Initial & Last Name & Degree
Pankaj Khandelwal, MD
Facility Name
Texas Oncology - West Texas (Joe Battle Dr)
City
El Paso
State/Province
Texas
ZIP/Postal Code
79938
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tanya Jauch Worley
Phone
915-747-4878
Email
tanya.jauchworley@usoncology.com
First Name & Middle Initial & Last Name & Degree
Pankaj Khandelwal, MD
Facility Name
Texas Oncology - Flower Mound - Carrollton
City
Flower Mound
State/Province
Texas
ZIP/Postal Code
75028
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology - Fort Worth Cancer Center
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology-Grapevine
City
Grapevine
State/Province
Texas
ZIP/Postal Code
76051
Country
United States
Individual Site Status
Completed
Facility Name
Valley Cancer Associates
City
Harlingen
State/Province
Texas
ZIP/Postal Code
78550
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology - Memorial City
City
Houston
State/Province
Texas
ZIP/Postal Code
77024
Country
United States
Individual Site Status
Completed
Facility Name
Oncology Consultants
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology Gulf Coast (Willowbrook)
City
Houston
State/Province
Texas
ZIP/Postal Code
77070
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology - Longview Cancer Center
City
Longview
State/Province
Texas
ZIP/Postal Code
75601
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shelly Maxfield
Phone
903-579-9840
Email
shelly.maxfield@usoncology.com
First Name & Middle Initial & Last Name & Degree
Donald Richards, MD
Facility Name
Texas Oncology - West Texas (Odessa)
City
Odessa
State/Province
Texas
ZIP/Postal Code
79761
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mary Williams
Phone
432-368-2138
Email
mary.williams2@usoncology.com
First Name & Middle Initial & Last Name & Degree
Pankaj Khandelwal, MD
Facility Name
Texas Oncology - Palestine
City
Palestine
State/Province
Texas
ZIP/Postal Code
75801
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shelly Maxfield
Phone
903-579-9840
Email
Shelly.maxfield@usoncology.com
First Name & Middle Initial & Last Name & Degree
Donald Richards, MD
Facility Name
Texas Oncology - Paris
City
Paris
State/Province
Texas
ZIP/Postal Code
75460
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sue Crumpler
Phone
903-785-0031
Email
sue.crumpler@usoncology.com
First Name & Middle Initial & Last Name & Degree
Donald Richards, MD
Facility Name
Texas Oncology - Plano East
City
Plano
State/Province
Texas
ZIP/Postal Code
75075
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erica Goetz
Phone
972-599-5860
Email
erica.goetz@usoncology.com
First Name & Middle Initial & Last Name & Degree
Carlos A. Taboada, MD
Facility Name
Texas Oncology - Tyler
City
Tyler
State/Province
Texas
ZIP/Postal Code
75702
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shelly Maxfield
Phone
903-579-9840
Email
shelly.maxfield@usoncology.com
First Name & Middle Initial & Last Name & Degree
Donald A. Richards, MD
Facility Name
Texas Oncology - Waco
City
Waco
State/Province
Texas
ZIP/Postal Code
76712
Country
United States
Individual Site Status
Completed
Facility Name
Texas Oncology Golf Coast - Deke Slayton Cancer Center
City
Webster
State/Province
Texas
ZIP/Postal Code
77598
Country
United States
Individual Site Status
Completed
Facility Name
Virginia Cancer Specialists, PC (Kenmore Ave)
City
Alexandria
State/Province
Virginia
ZIP/Postal Code
22304
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Monica Cochrane
Phone
703-208-3110
Email
monica.cochrane@usoncology.com
First Name & Middle Initial & Last Name & Degree
Timothy McCarthy, MD
Facility Name
Virginia Cancer Specialists, PC (N George Mason Dr)
City
Arlington
State/Province
Virginia
ZIP/Postal Code
22205
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ebtehal Al Shami
Phone
703-894-3891
Email
ebtehal.alshami@usoncology.com
First Name & Middle Initial & Last Name & Degree
Timothy McCarthy, MD
Facility Name
Virginia Cancer Specialists, PC
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shelby Dukes
Phone
571-222-2273
Email
shelby.dukes@usoncology.com
First Name & Middle Initial & Last Name & Degree
Timothy McCarthy, MD
Facility Name
Virginia Cancer Specialists, PC (Lake Manassas Dr)
City
Gainesville
State/Province
Virginia
ZIP/Postal Code
20155
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shelby Dukes
Phone
571-222-2273
Email
shelby.dukes@usoncology.com
First Name & Middle Initial & Last Name & Degree
Timothy McCarthy, MD
Facility Name
Virginia Cancer Specialists, PC (Riverside Pkwy)
City
Leesburg
State/Province
Virginia
ZIP/Postal Code
20176
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jutta McGovern
Phone
703-280-5390
Email
jutta.mcgovern@usoncology.com
First Name & Middle Initial & Last Name & Degree
Timothy McCarthy, MD
Facility Name
Providence Regional Cancer Partnership
City
Everett
State/Province
Washington
ZIP/Postal Code
98201
Country
United States
Individual Site Status
Completed
Facility Name
MultiCare Regional Cancer Center
City
Spokane
State/Province
Washington
ZIP/Postal Code
99204
Country
United States
Individual Site Status
Completed
Facility Name
West Virginia University Cancer Institute
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26506
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carla Ross
Phone
304-293-2991
Email
carla.ross@hsc.wvu.edu
First Name & Middle Initial & Last Name & Degree
Mohammed Almubarak, MD
Facility Name
Gold Coast Cancer Care - Pindara
City
Benowa
State/Province
Queensland
ZIP/Postal Code
4217
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zelda Van Biljon
Phone
61 075588 9008
Email
vanbiljonZ@ramsayhealth.com.au
First Name & Middle Initial & Last Name & Degree
Marco Matos, MD
Facility Name
Flinders Medical Centre
City
Bedford Park
State/Province
South Australia
ZIP/Postal Code
5042
Country
Australia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tielei Kong
Phone
088204 6151
Email
Tielei.kong@sa.gov.au
First Name & Middle Initial & Last Name & Degree
Christos Karapetis, MD
Facility Name
Ballarat Regional Integrated Cancer Center
City
Ballarat
State/Province
Victoria
ZIP/Postal Code
3350
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lisa Bell
Phone
03 5320 8517
Email
Lisa.Bell@bhs.org.au
First Name & Middle Initial & Last Name & Degree
Wasek Faisal, MD
Facility Name
High Technology Hospital MedCenter Ltd - Batumi
City
Batumi
State/Province
Adjara
ZIP/Postal Code
6000
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mamuka Sikharulidze
Phone
995 577 574 770
Email
Sikharulidzemamuka3@gmail.com
First Name & Middle Initial & Last Name & Degree
Tamta Makharadze, MD
Facility Name
Tbilisi Institute of Medicine
City
Tbilisi
State/Province
Tbilisa
ZIP/Postal Code
0160
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ekaterine Jincharadze
Phone
995 557 565 674
Email
j.ekaterine@yahoo.com
First Name & Middle Initial & Last Name & Degree
Mariam Zhvania, MD
Facility Name
Evex Hospitals - Kutaisi Referral Hospital
City
Kutaisi
ZIP/Postal Code
4600
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Melania Godoladze
Phone
995 579 164 165
Email
melaniegodoladze@gmail.com
First Name & Middle Initial & Last Name & Degree
Khatuna Bibichadze, MD
Facility Name
Healthycore - Israel-Georgia Medical Research Clinic Helsikor
City
Tbilisi
ZIP/Postal Code
0112
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vera Markhulia
Phone
995 598 149 995
Email
veramarkhulia@gmail.com
First Name & Middle Initial & Last Name & Degree
Ekaterine Arkania, MD
Facility Name
LLC Todua Clinic
City
Tbilisi
ZIP/Postal Code
0112
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mariam Lomidze
Phone
995 593 020 320
Email
Mlomidze86@gmail.com
First Name & Middle Initial & Last Name & Degree
Tamar Melkadze, MD
Facility Name
Ltd Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
City
Tbilisi
ZIP/Postal Code
0144
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mariam Vardukadze
Phone
995 555 737 822
Email
Mariamivardukadze7777@gmail.com
First Name & Middle Initial & Last Name & Degree
Miranda Gogishvili, MD
Facility Name
Mardaleishvili Medical Center
City
Tbilisi
ZIP/Postal Code
0177
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Salome Tvaladze
Phone
995 599 233 698
Email
salometvaladze@gmail.com
First Name & Middle Initial & Last Name & Degree
Amiran Matitashvili, MD
Facility Name
Consilium Medulla Multiprofile Clinic
City
Tbilisi
ZIP/Postal Code
0186
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Megi Kamadadze
Phone
995 597 602 404
Email
maggie.kamadadze@gmail.com
First Name & Middle Initial & Last Name & Degree
Tsira Kortua, MD
Facility Name
Evex Hospitals - Caraps Medline
City
Tbilisi
ZIP/Postal Code
159
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shorena Kratsashvili
Phone
995 599 586 454
Email
sho_kratsashvili@yahoo.com
First Name & Middle Initial & Last Name & Degree
Nana Chikhladze, MD
Facility Name
Evex Hospitals - Caucasus Medical Center
City
Tbilisi
ZIP/Postal Code
186
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nino Khunashvili
Phone
995 551 375 375
Email
Ninokhunashvili.2@gmail.com
First Name & Middle Initial & Last Name & Degree
Ivane Kiladze, MD
Facility Name
MSB - Medicinski Sistem Beograd
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Violeta Mihailovic-Vucinic, MD
First Name & Middle Initial & Last Name & Degree
Violeta Mihailovic-Vucinic, MD
Facility Name
University Hospital Medical Center (KBC) Bezanijska Kosa
City
Belgrade
ZIP/Postal Code
11080
Country
Serbia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zoran Andric, MD
First Name & Middle Initial & Last Name & Degree
Zoran Andric, MD
Facility Name
University Clinical Center of Serbia
City
Belgrad
ZIP/Postal Code
11129
Country
Serbia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Milica Kontic Jovanovic, MD
First Name & Middle Initial & Last Name & Degree
Milica Kontic Jovanovic, MD
Facility Name
Clinical Center Kragujevac
City
Kragujevac
ZIP/Postal Code
34000
Country
Serbia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marina Petrovic, MD
First Name & Middle Initial & Last Name & Degree
Marina Petrovic, MD
Facility Name
Institute for Pulmonary Diseases of Vojvodina
City
Sremska Kamenica
ZIP/Postal Code
21204
Country
Serbia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bojan Zaric, MD
First Name & Middle Initial & Last Name & Degree
Bojan Zaric, MD
Facility Name
Uzice General Hospital
City
Užice
ZIP/Postal Code
31000
Country
Serbia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zorica Radojevic, MD
First Name & Middle Initial & Last Name & Degree
Zorica Radojevic, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

We'll reach out to this number within 24 hrs